Anlon Healthcare IPO Allotment Status

Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs), incorporated in 2013. The company manufactures high-purity pharmaceutical intermediates for API production and active pharmaceutical ingredients used in formulations for medicines, nutraceuticals, personal care, and animal health products following Indian and international pharmacopeia standards, with a product portfolio consisting of sixty-five commercialized products, twenty-eight products at pilot stage, and forty-nine products at laboratory testing stage, supported by a 34-member team including 24 science graduates across four laboratories.

The Anlon Healthcare IPO came with a total issue size of ₹121.03 crore, comprising entirely a fresh issue of 1.33 crore shares aggregating to ₹121.03 crore. The IPO opened on August 26, 2025, and closed on August 29, 2025. The allotment for the Anlon Healthcare IPO is expected to be finalized on Monday, September 1, 2025. The Anlon Healthcare IPO share price band was set at ₹86 to ₹91 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Anlon Healthcare IPO Allotment Status on Registrar Site

• Visit the Kfin Technologies Ltd. website 
• Select "Anlon Healthcare" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Anlon Healthcare IPO Allotment Status on BSE

• Navigate to the BSE IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Anlon Healthcare" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Anlon Healthcare IPO Subscription Status

Anlon Healthcare IPO received strong investor interest, being subscribed 7.12 times overall. The subscription showed mixed confidence across categories in the Anlon Healthcare IPO stock price potential. Here is a category-wise breakdown of the subscription as of 5:04:36 PM on August 29, 2025:

• Non-Institutional Investors (NII): 10.61 times.
• QIB Category: 1.07 times.

Anlon Healthcare IPO Share Price and Investment Details

The Anlon Healthcare IPO stock price band was set at ₹86 to ₹91 per share with a minimum lot size of 164 shares. The minimum investment required for retail investors was ₹14,924 for 1 lot (164 shares). The issue did not include anchor investor allocation. Given the strong subscription response of 7.12 times overall, with QIB category showing minimal response at 1.07 times and retail investors demonstrating exceptional response at 47.26 times, the Anlon Healthcare IPO share price is expected to list with good to strong premium.

Utilisation of IPO Proceeds

The funds raised through the IPO will be utilised as follows:

• Funding capital expenditure requirements for Proposed Expansion: ₹30.72 crore.
• Full or part repayment and/or prepayment of certain outstanding secured borrowings: ₹5.00 crore.
• Funding the working capital requirements of the Company: ₹43.15 crore.
• General corporate purposes: Remaining amount.

Business Overview

Anlon Healthcare Limited is a chemical manufacturing company specializing in pharmaceutical intermediates and active pharmaceutical ingredients manufactured to global standards, offering custom manufacturing for complex chemicals exceeding purity standards while serving formulations for medicines, nutraceuticals, personal care, and veterinary products. The company has received Drug Master File approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs, with 21 DMFs filed with global authorities and additional approvals in process for Ketoprofen and Dexketoprofen Trometamol. With strong product portfolio featuring scalable business model, experienced management team, high entry and exit barriers due to long customer approval cycles, in-house testing and quality control capabilities, the company maintains focus on quality, environment, health and safety while ensuring rigorous testing, analysis, and process improvements to meet customer and industry standards across its comprehensive product range from laboratory scale to commercialized offerings.